Exclusive Speaker Interview from Seattle Genetics for SMi’s ADC Conference This April
London, United Kingdom, February 07, 2018 --(PR.com)-- SMi are delighted to welcome Robert Lyon, Senior Director Protein Sciences, Seattle Genetics Ltd, onto the speaker panel for day 2 at ADC 2018.
About Robert:
Robert Lyon received in PhD in Medicinal Chemistry from the University of Washington in 2002. Since joining Seattle Genetics in 2005, he has made numerous contributions to the field of antibody-drug conjugates, with a particular emphasis on understanding and improving ADC disposition. Dr. Lyon is currently a Senior Director in the Protein Sciences Department, where he continues to lead efforts to innovate optimal ADC technologies.
SMi are excited to have interviewed Robert about his talk and career experience.
Below is a snapshot of his interview:
Q. How is your organisation involved in Antibodies and Antibody Drug Conjugates?
A. Seattle Genetics has been involved in ADC R&D for more than 15 years, and most conference attendees will probably be familiar with Adcetris, our first marketed product that received its first approval in 2011. Our pipeline includes seven additional ADCs utilizing three distinct technology platforms, with many other candidates in trials sponsored by our licensees. We also have an unconjugated antibody currently in the clinic that utilizes our production platform for creating non-fucosylated antibodies with enhanced effector function.
Q. Which markets are you looking to collaborate with in the future?
A. Seattle Genetics will continue to look for partnering opportunities in all aspects of antibody and ADC technologies, including academic investigators and fellow biotechnology firms.
Q. What are the key areas for development in the field of ADCs?
A. Clearly the various technologies that have been tested in the clinic have shown considerable variability in their tolerability profiles.
Q. What are the future challenges for the advancement of ADCs and what do you think are the biggest hindrances to achieving the utmost therapeutic potential of ADCs?
Check out the download centre online for the full interview.
Hear more from Seattle Genetics at the Antibodies & Antibody Drug Conjugates conference this April 2018, as he presents a Keynote on: 'Design Principles for Maximizing the Drug Delivery Efficiency and Therapeutic Index of ADCs.' - Day 2 | @11:40.
View the interview and further information at: www.adcsummit.com/prc
SMi presents the 6th Annual Conference:
ADC Summit
Date: 9th – 10th April 2018
Location: Copthorne Tara Hotel, London UK
Website: www.adcsummit.com/prc
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
About Robert:
Robert Lyon received in PhD in Medicinal Chemistry from the University of Washington in 2002. Since joining Seattle Genetics in 2005, he has made numerous contributions to the field of antibody-drug conjugates, with a particular emphasis on understanding and improving ADC disposition. Dr. Lyon is currently a Senior Director in the Protein Sciences Department, where he continues to lead efforts to innovate optimal ADC technologies.
SMi are excited to have interviewed Robert about his talk and career experience.
Below is a snapshot of his interview:
Q. How is your organisation involved in Antibodies and Antibody Drug Conjugates?
A. Seattle Genetics has been involved in ADC R&D for more than 15 years, and most conference attendees will probably be familiar with Adcetris, our first marketed product that received its first approval in 2011. Our pipeline includes seven additional ADCs utilizing three distinct technology platforms, with many other candidates in trials sponsored by our licensees. We also have an unconjugated antibody currently in the clinic that utilizes our production platform for creating non-fucosylated antibodies with enhanced effector function.
Q. Which markets are you looking to collaborate with in the future?
A. Seattle Genetics will continue to look for partnering opportunities in all aspects of antibody and ADC technologies, including academic investigators and fellow biotechnology firms.
Q. What are the key areas for development in the field of ADCs?
A. Clearly the various technologies that have been tested in the clinic have shown considerable variability in their tolerability profiles.
Q. What are the future challenges for the advancement of ADCs and what do you think are the biggest hindrances to achieving the utmost therapeutic potential of ADCs?
Check out the download centre online for the full interview.
Hear more from Seattle Genetics at the Antibodies & Antibody Drug Conjugates conference this April 2018, as he presents a Keynote on: 'Design Principles for Maximizing the Drug Delivery Efficiency and Therapeutic Index of ADCs.' - Day 2 | @11:40.
View the interview and further information at: www.adcsummit.com/prc
SMi presents the 6th Annual Conference:
ADC Summit
Date: 9th – 10th April 2018
Location: Copthorne Tara Hotel, London UK
Website: www.adcsummit.com/prc
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Pav Solanki
+44 (0) 207 827 6048
www.adcsummit.com/prc
Pav Solanki
+44 (0) 207 827 6048
www.adcsummit.com/prc
Contact
Categories